Defence Therapeutics AccuVAC-D001 Cancer Vaccine Generates Effective Long-lasting Anti-Tumoral Response
Vancouver, British Columbia--(Newsfile Corp. - May 25, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), is pleased to announce the completion of its AccuVAC-D001 cancer vaccine pre-clinical study. The AccuVAC-D001 cancer vaccine demonstrated a 70% cure rate of mice with pre-established solid tumors, this AccuVAC-D001 cancer vaccine confirms an effective anti-tumoral response. Non-specific degradation of endocytosed cancer antigens by endo-lysosomal organelles in...
2021-05-25 3:30 AM EDT
Defence Therapeutics, Strong Therapeutics Pipeline: ADC's, Cancer and COVID Vaccines
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2021) - Defence Therapeutics Inc. (CSE: DTC) ("Defence" or the "Company"), a Canadian biotech Company focused on the development of novel and highly specific vaccines and antibody-drug conjugates targeting cancer and infectious diseases, is pleased to begin its trading on the CSE as of today. The primary objective and business of Defence is the research, development and advancement of three main products using its proprietary Accum...
2021-05-07 8:00 AM EDT